Autopsy report · NCT06677710

IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis

“Business Reasons”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 8 months before it started.
• Suspended: paused, and may or may not restart.
• 34 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Phase

Phase 1

Sponsor

Indapta Therapeutics, INC.

Sponsor type

Industry

Conditions

Multiple Sclerosis; Primary Progressive Multiple Sclerosis (PPMS); Secondary Progressive Multiple Sclerosis (SPMS); Non-Active Secondary Progressive Multiple Sclerosis; Non-Active SPMS; Autoimmune Diseases of the Nervous System

Interventions

IDP-023; Ocrelizumab; Interleukin-2; Cyclophosphamide; Fludarabine; Mesna

Participants

34 (planned, not actual)

Sites

5

Countries

United States

Trials that died the same way

• StrataGraft Overlay of Meshed Autograft in Full-thickness Thermal Burns
  “Business Reason” (94% match in meaning)
• Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
  “Financial/Business Reasons” (88% match in meaning)
• First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
  “Business/Commercial Reasons” (87% match in meaning)
• Effect of Timing of Tumor-Treating Fields Plus Short-Course Radiation
  “Organizational reasons” (85% match in meaning)
• Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance
  “for business reasons” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.